Analysis of NFAT-regulated gene expression in vivo: A novel perspective for optimal individualized doses of calcineurin inhibitors

Nephrology Dialysis Transplantation

Volumn 19, Issue SUPPL. 4, 2004, Pages

  Giese, Thomas ^a   Zeier, Martin ^a   Meuer, Stefan ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Cyclosporine A; Expression analysis; Immunosuppression; Transplantation

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; IONOMYCIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PHORBOL 13 ACETATE 12 MYRISTATE; TRANSCRIPTION FACTOR NFAT;

ACCURACY; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXPOSURE; DRUG USE; FEMALE; GENE EXPRESSION REGULATION; HUMAN; HYALINE DEGENERATION; IMMUNOSUPPRESSIVE TREATMENT; IN VIVO STUDY; INDIVIDUALIZATION; KIDNEY ALLOGRAFT; KIDNEY FIBROSIS; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; NEPHROTOXICITY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RELIABILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCORING SYSTEM; TIME;

ADULT; AGED; AREA UNDER CURVE; CALCINEURIN; CYCLOSPORINE; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION REGULATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; NFATC TRANSCRIPTION FACTORS; NUCLEAR PROTEINS; TRANSCRIPTION FACTORS;

EID: 4344653892     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfh1043     Document Type: Article

References (16)

1. Hariharan S, Johnson CP, Bresnahan BA et al. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 2000; 342: 605-612
2. Sommerer C, Hergesell O, Nahm AM et al. Cyclosporin A toxicity of the renal allograft-a late complication and potentially reversible. Nephron 2002; 92: 339-345
3. Taylor DO. Immunosuppressive therapies after heart transplantation: best, better and beyond. Curr Opin Cardiol 2000; 15: 108-114
4. Fernandez-Marmiesse A, Hermida J, Tutor JC. Comparison of predose vs 2-h postdose blood metabolites/cyclosporine ratios in kidney and liver transplant patients. Clin Biochem 2000; 33: 383-386
5. del Mar Fernandez De Gatta M, Santos-Buelga D, Dominguez-Gil A, Garcia MJ. Immunosuppressive therapy for paediatric transplant patients: pharmacokinetic considerations. Clin Pharmacokinet 2002; 41: 115-135
6. Morris RG, Russ GR, Cervelli MJ et al. Comparison of trough, 2-hour and limited AUC blood sampling for monitoring cyclosporin (Neoral) at day 7 post-renal transplantation and incidence of rejection in the first month. Ther Drug Monit 2002; 24: 479-486
7. Kahan BD. The evolution of therapeutic drug monitoring of cyclosporine. Transplant Proc 2001; 33: 3086-3088
8. Maham N, Cardella C, Cattran D et al. Optimization of cyclosporine exposure utilizing C (2) level monitoring in de novo renal transplant recipients: the Toronto General Hospital experience. Transplant Proc 2001; 33: 3098-3099
9. Levy G, Burra P, Cavallari A et al. Improved clinical outcomes for liver transplant recipients using cyclosporine monitoring based on 2-hr post-dose levels (C2). Transplantation 2002; 73: 953-959
10. Halloran PF, Helms LM, Kung L, Noujaim J. The temporal profile of calcineurin inhibition by cyclosporine in vivo. Transplantation 1999; 68: 1356-1361
11. Sindhi R, LaVia MF, Paulling E et al. Stimulated response of peripheral lymphocytes may distinguish cyclosporine effect in renal transplant recipients receiving a cyclosporine+rapamycin regimen. Transplantation 2000; 69: 432-436
12. Kel A, Kel-Margoulis O, Babenko V, Wingender E. Recognition of NFATp/AP-1 composite elements within genes induced upon the activation of immune cells. J Mol Biol 1999; 288: 353-376
13. Giese T. Development of quantitative RT-PCR tests for the expression of cytokine genes on the LightCycler. In: Meuer S, Wittwer C, Nakagawara K, eds. Rapid Cycle Real-Time PCR: Methods and Applications. Springer, Berlin, Heidelberg, New York: 2001; 251-261
14. Batiuk TD, Pazderka F, Enns J, DeCastro L, Halloran PF. Cyclosporine inhibition of calcineurin activity in human leukocytes in vivo is rapidly reversible. J Clin Invest 1995; 96: 1254-1260
15. Batiuk TD, Pazderka F, Enns J, De Castro L, Halloran PF. Cyclosporine inhibition of leukocyte calcineurin is much less in whole blood than in culture medium. Transplantation 1996; 61: 158-161
16. Dumont RJ, Ensom MH. Methods for clinical monitoring of cyclosporin in transplant patients. Clin Pharmacokinet 2000; 38: 427-447